Hui Shao, YS Biopharma president and CEO (L) and Yi Zhang, founder and chairman

Chi­na’s Yisheng­Bio is go­ing to Nas­daq, mak­ing the tran­si­tion via $230M SPAC ma­neu­ver

Af­ter at­tempt­ing to make it on the HKEX last year, a Chi­nese bio­phar­ma is fi­nal­ly tak­ing the once-flashy SPAC route to get on the Nas­daq.

Yisheng­Bio — which will be re­named YS Bio­phar­ma, per a Thurs­day state­ment — will be com­bin­ing with Hong Kong-based Sum­mit Health­care Ac­qui­si­tion Corp, cur­rent­ly list­ed on Nas­daq un­der the tick­er $SMIH af­ter launch­ing on the stock ex­change last year. If every­thing goes to plan, the merg­er will be fin­ished in Q1 next year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.